Ann: Phase III prophylaxis trial for CS-8958 , page-14

http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090941

The primary objective of this study is to confirm the efficacy of CS-8958 (given once weekly, two times in total) to prevent influenza virus infection among household contacts of influenza-infected cases. For safety evaluation, between-group comparisons will be made with regard to incidence of adverse events and other safety measures.

*************In a secondary objective, the optimum dosage of CS-8958 for this indication will be estimated based on the efficacy and safety***************